{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:04:51Z","timestamp":1784099091134,"version":"3.55.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Concentrations of fibroblast growth factor 23 (FGF-23), a hormone that regulates phosphorus and vitamin D metabolism, increase as kidney function declines. Excess fibroblast growth factor 23 may impact brain function through promotion of vascular disease or through direct effects on neuronal tissue.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In the Healthy Aging and Body Composition Study, a longitudinal observational cohort of well-functioning older adults, intact serum FGF-23 was assayed in 2,738 individuals. Cognitive function was assessed at baseline and longitudinally at years 3, 5, and 8 by administration of the Modified Mini Mental State Examination (3MSE), a test of global cognitive function, and the Digit Symbol Substitution Test (DSST), a test primarily of executive function. The associations between FGF-23 and baseline cognitive function and incident cognitive impairment were evaluated using logistic and Poisson regression respectively, and were adjusted for demographics, baseline estimated glomerular filtration rate (eGFR), urine albumin\/creatinine ratio, comorbidity, and other measures of mineral metabolism including soluble klotho.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The mean (SD) age was 74(3) years, with 51% female, and 39% black. The median (25th, 75th) FGF-23 concentration was 47 pg\/mL (37, 60). Three hundred ninety-two individuals had prevalent cognitive impairment by the 3MSE and 461 by the DSST. There was no observed association between FGF-23 and baseline cognitive function for either cognitive test. There were 277 persons with incident cognitive impairment by 3MSE, and 333 persons with incident cognitive impairment by DSST. In fully adjusted models, each two-fold higher concentration of baseline FGF-23 was not associated with incident cognitive impairment by the 3MSE (IRR = 1.02[0.88, 1.19] fully adjusted model) or by the DSST (IRR = 0.98 [0.84, 1.15]. We saw no difference when analyses were stratified by eGFR greater than or less than 60 ml\/min\/1.73m<jats:sup>2<\/jats:sup>.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Intact FGF-23 was not associated with baseline cognitive function or incident cognitive impairment in this cohort well-functioning older adults.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0243872","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T18:50:00Z","timestamp":1607712600000},"page":"e0243872","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fibroblast growth factor 23 and cognitive impairment: The health, aging, and body composition study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-723X","authenticated-orcid":true,"given":"David A.","family":"Drew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kritchevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shlipak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-3571","authenticated-orcid":true,"given":"Orlando M.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sarnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"issue":"2","key":"pone.0243872.ref001","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1532-5415.2009.02670.x","article-title":"Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study","volume":"58","author":"K Yaffe","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"pone.0243872.ref002","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2215\/CJN.02660310","article-title":"Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study.","volume":"6","author":"M Kurella Tamura","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"pone.0243872.ref003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living IndividualsCHS (Cardiovascular Health Study).","volume":"60","author":"JH Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0243872.ref004","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","article-title":"Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the Brain","volume":"277","author":"T Yamashita","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0243872.ref005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/hdi.12100","article-title":"FGF-23 and cognitive performance in hemodialysis patients","volume":"18","author":"DA Drew","year":"2014","journal-title":"Hemodial Int"},{"issue":"3","key":"pone.0243872.ref006","doi-asserted-by":"crossref","first-page":"e0213321","DOI":"10.1371\/journal.pone.0213321","article-title":"Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study","volume":"14","author":"ER McGrath","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"pone.0243872.ref007","doi-asserted-by":"crossref","first-page":"e0165671","DOI":"10.1371\/journal.pone.0165671","article-title":"fibroblast growth factor 23 and incident cognitive impairment: findings from the REGARDS study","volume":"11","author":"B Panwar","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"pone.0243872.ref008","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5414\/CN108365","article-title":"25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population","volume":"82","author":"AJ Jovanovich","year":"2014","journal-title":"Clin Nephrol"},{"issue":"2","key":"pone.0243872.ref009","first-page":"114","article-title":"The Modified Mini-Mental State Examination (3MS)","volume":"41","author":"E Teng","year":"1987","journal-title":"Can J Psychiatry"},{"key":"pone.0243872.ref010","volume-title":"Wais-III, Wechsler Adult Intelligence Scale, Third Edition: WMS-III, Wechsler Memory Scale, Third Edition: Technical Manual","author":"D Wechsler","year":"2002"},{"issue":"11","key":"pone.0243872.ref011","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","article-title":"Evaluating storage, retention, and retrieval in disordered memory and learning","volume":"24","author":"H Buschke","year":"1974","journal-title":"Neurology"},{"issue":"1","key":"pone.0243872.ref012","doi-asserted-by":"crossref","first-page":"P30","DOI":"10.1093\/geronb\/51B.1.P30","article-title":"General and specific speed mediation of adult age differences in memory. The Journals of Gerontology Series B","volume":"51","author":"TA Salthouse","year":"1996","journal-title":"Psychological Sciences and Social Sciences"},{"key":"pone.0243872.ref013","article-title":"Bedside assessment of executive cognitive impairment: the executive interview","author":"DR Royall","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"pone.0243872.ref014","article-title":"The Modified Mini-Mental State (3MS) examination","volume":"48","author":"EL Teng","year":"1987","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"pone.0243872.ref015","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2005010005","article-title":"Chronic Kidney Disease and Cognitive Impairment in the Elderly: The Health, Aging, and Body Composition Study","volume":"16","author":"M Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0243872.ref016","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ana.21383","article-title":"Cystatin C as a marker of cognitive function in elders: Findings from the health ABC study","volume":"63","author":"K Yaffe","year":"2008","journal-title":"Ann Neurol"},{"issue":"3","key":"pone.0243872.ref017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD","volume":"51","author":"LA Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"pone.0243872.ref018","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD","volume":"51","author":"LA Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"pone.0243872.ref019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C","volume":"367","author":"LA Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0243872.ref020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbrc.2010.06.110","article-title":"Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects","volume":"398","author":"Y Yamazaki","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0243872.ref021","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/hdi.12100","article-title":"FGF\u201023 and cognitive performance in hemodialysis patients.","volume":"18","author":"DA Drew","year":"2014","journal-title":"Hemodialysis International"},{"issue":"12","key":"pone.0243872.ref022","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"T Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"pone.0243872.ref023","first-page":"ASN. 2014121253","article-title":"Renal clearance of mineral metabolism biomarkers","author":"AJ van Ballegooijen","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0243872.ref024","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2004-1039","article-title":"Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men","volume":"90","author":"SL Ferrari","year":"2005","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"pone.0243872.ref025","first-page":"923","article-title":"Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage","volume":"47","author":"CB Wright","year":"2016","journal-title":"The Northern Manhattan Study"},{"issue":"19","key":"pone.0243872.ref026","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"OM Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"pone.0243872.ref027","doi-asserted-by":"crossref","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"C Faul","year":"2011","journal-title":"The Journal of clinical investigation"},{"issue":"10","key":"pone.0243872.ref028","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/01.STR.0000089680.77236.60","article-title":"Left ventricular mass and geometry and the risk of ischemic stroke","volume":"34","author":"MR Di Tullio","year":"2003","journal-title":"Stroke"},{"issue":"10","key":"pone.0243872.ref029","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1161\/01.STR.0000239694.19359.88","article-title":"Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study","volume":"37","author":"T Ohira","year":"2006","journal-title":"Stroke"},{"issue":"19","key":"pone.0243872.ref030","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1212\/WNL.0b013e318236ef23","article-title":"Vascular risk factors and cognitive impairment in a stroke-free cohort","volume":"77","author":"F Unverzagt","year":"2011","journal-title":"Neurology"},{"key":"pone.0243872.ref031","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","author":"V David","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0243872.ref032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ndt\/gft456","article-title":"Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease","volume":"29","author":"A Bouma-de Krijger","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"pone.0243872.ref033","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00198-016-3543-5","article-title":"Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type","volume":"27","author":"D. El-Maouche","year":"2016","journal-title":"Osteoporosis International"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T18:50:21Z","timestamp":1607712621000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243872"}},"subtitle":[],"editor":[{"given":"Stephen D.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243872","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}